SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001640455-22-000069
Filing Date
2022-06-28
Accepted
2022-06-28 21:02:17
Documents
1
Period of Report
2022-06-24

Document Format Files

Seq Description Document Type Size
1 FORM 4 wf-form4_165646451016548.html 4  
1 FORM 4 wf-form4_165646451016548.xml 4 4162
  Complete submission text file 0001640455-22-000069.txt   5548
Mailing Address C/O INTERCEPT PHARMACEUTICALS, INC. 18 DESBROSSES STREET NEW YORK NY 10013
Business Address
Duncan Barbara Gayle (Reporting) CIK: 0001353128 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37998 | Film No.: 221051570

Mailing Address 780 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 780 MEMORIAL DRIVE CAMBRIDGE MA 02139 857-259-3840
Jounce Therapeutics, Inc. (Issuer) CIK: 0001640455 (see all company filings)

IRS No.: 454870634 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)